R&D for Development of New Drugs for Neglected Diseases How Can India Contribte?
AbstractThe focus of this paper is India. In line with TRIPS India has introduced a product patent regime in pharmaceuticals from 1 January, 2005. WIll this lead increase in resources deveoted to R and D by Indian companies for the development of new drugs more suited to the needs of India and other developing countries? Can the innovation capabilities be utilized for developing new drugs for neglected diseases? Can India contribte to lowering the cost of new drug development and make drugs more accessible?
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by eSocialSciences in its series Working Papers with number id:2149.
Date of creation: Jul 2009
Date of revision:
Note: Institutional Papers
Contact details of provider:
Web page: http://www.esocialsciences.org
India; resources; TRIPS; pharmaceuticals; developing countries; drugs; diseases; development; developing countries; developed countries; R&D;
This paper has been announced in the following NEP Reports:
- NEP-ALL-2009-08-08 (All new papers)
- NEP-CWA-2009-08-08 (Central & Western Asia)
- NEP-INO-2009-08-08 (Innovation)
You can help add them by filling out this form.
reading list or among the top items on IDEAS.Access and download statisticsgeneral information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Padma Prakash).
If references are entirely missing, you can add them using this form.